Shares of uniQure N.V. (QURE) managed a slight uptick on Wednesday. But let's be honest, that's like saying you found a quarter after your wallet fell into a storm drain. The real story is the 40% plunge the day before, a direct result of the U.S. Food and Drug Administration delivering some tough news about the company's investigational gene therapy for Huntington's disease.

The sharp decline came after the FDA advised against using data from the ongoing Phase 1/2 study as the primary evidence for a marketing application of the therapy, called AMT-130. This throws a major wrench into uniQure's plans and raises big questions about the therapy's path to approval.

The FDA Wants a More Rigorous Test

Here's the core of the issue. On Monday, the FDA strongly recommended that uniQure conduct a new study. Not just any study, but a prospective, randomized, double-blind, sham surgery-controlled study. In plain English, that means a much more rigorous and time-consuming trial where some patients receive a placebo procedure. It's the gold standard for proving a treatment works, but it's not the fast track uniQure was hoping for.

Back in November, the company thought the data from its earlier studies might be enough to support a Biologics License Application (BLA) submission. The FDA's latest stance suggests that's not going to fly. In response, uniQure says it plans to request a formal meeting with the FDA in the second quarter of 2026 to discuss the therapy's development plan further.

This setback hits at a critical time as uniQure is trying to advance its pipeline of gene therapies for severe diseases like Huntington's, refractory temporal lobe epilepsy, ALS, and Fabry disease.

Where the Stock Stands Now

So, what does the chart say after this kind of news? The picture is bearish. The stock is currently trading 14.29% below its 20-day simple moving average and a hefty 30.00% below its 100-day average. Shares have taken a beating over the past year and are sitting much closer to their 52-week lows than their highs.

The Relative Strength Index (RSI) is right at 50.00, which is neutral territory—neither oversold nor overbought. Meanwhile, the MACD indicator is at -0.10, sitting below its signal line, which points to ongoing bearish pressure. It's a mix of neutral and negative signals.

• Key Resistance: $10.00
• Key Support: $8.00

What Are the Analysts Saying? The consensus rating on the stock is still a Buy, with an average price target of $39.69. But that lofty figure likely reflects older, more optimistic assumptions. The recent analyst moves tell a more immediate story of reassessment:

• Goldman Sachs: Maintained Neutral rating but lowered its price target to $9.00 (March 3).
• Wells Fargo: Downgraded the stock to Equal-Weight from Overweight and slashed its target to $15.00 (March 3).
• Chardan Capital: Maintained a Buy rating but lowered its target to $16.00 (March 3).

The Bottom Line: At the time of publication on Wednesday, uniQure shares were up 1.50% at $9.16. The stock is trading perilously close to its 52-week low of $7.76. The minor bounce is a blip; the real narrative is a company whose lead candidate just hit a significant regulatory speed bump, sending investors scrambling and analysts back to their calculators.